beractant

beractant

 [ber-ak´tant]
a substance obtained from bovine lungs, containing mostly phospholipids; it mimics the action of human pulmonary surfactant and is used in prevention and treatment of respiratory distress syndrome of the newborn. Administered by endotracheal intubation.

beractant

/ber·ac·tant/ (ber-ak´tant) a modified bovine lung extract that mimics the action of pulmonary surfactant, used in the prevention and treatment of respiratory distress syndrome of the newborn.

beractant

[ber-ak′tant]
a substance obtained from bovine lungs, containing mostly phospholipids. It mimics the action of human pulmonary surfactant and is used in prevention and treatment of respiratory distress syndrome of the newborn. Administered by endotracheal intubation.

beractant

A SURFACTANT drug used in the treatment of the RESPIRATORY DISTRESS SYNDROME. A brand name is Survanta.
References in periodicals archive ?
was highlighted in the December issue of the Journal of Pediatric Pharmacology and Therapeutics(JPPT), in an article titled "A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa", as well as this month's issue of Expert Reviews in Clinical Pharmacology in an article titled "Lucinactant for the Prevention of Respiratory Distress Syndrome in Premature Infants".
Birimimizde dogum odasinda entubasyon gereksinimi olan 30 haftaliktan kucuk bebeklere ilk 15 dakika icinde surfaktan uygulanirken, 30 haftanin ustundeki bebeklere erken kurtarma tedavisi seklinde ilk iki saat icinde 100/mg/kg dozunda beractant (Survanta) uygulanmaktadir.
The results concluded that KL-4 surfactant reduced inflammation and cell injury, resulting in improved cell survival and function compared with both a saline control as well as beractant (Survanta(r)), an animal-derived surfactant and currently the most frequently prescribed surfactant in the United States.
The marketers of Curosurf (Chiesi Farmaceutici SpA in the European Union and Dey Laboratories, LP in the USA) have sponsored a series of small clinical trials that have compared the acute response of patients to prophylactic treatment at birth with poractant alfa or beractant.
At the Academic Pediatric Society meetings in 2007 in Toronto, a retrospective, epidemiologic paper was presented that reported that Curosurf patients experienced a lower all cause in-hospital mortality than beractant or calfactant patients.
Last, there is nothing in the composition, biophysical properties, or biologic activity of poractant alfa compared to beractant or calfactant that can explain a mortality benefit.
Lucinactant Comparison Trial to Colfosceril palmitate and Beractant
Lioresal baclofen Treatment of intractable Intrathecal spasticity caused by spinal cord injury, multiple sclerosis, other spinal diseases Lupron injection leuprolide acetate Treatment of central Prolastin alpha-1 -proteinase precocious puberty inhibitor (human) Replacement therapy in the alpha-1 -proteinase inhibitor congenital deficiency state Survanta beractant Prevention and treatment of intratracheal neonatal respiratory suspension distress syndrome.
Examples of natural surfactant include Beractant (Survanta), Poractant Alfa (Curosurf), and Clafactant (Infasurf)
Beractant (Survanta) is considered a modified natural surfactant.
For both groups, death rates were nearly 20% lower for babies treated with poractant alfa than for those treated with either beractant or calfactant.
In a randomized, multi- center trial that was published in the American Journal of Perinatology in 2004, we found a significantly higher survival rate among RDS babies treated with poractant alfa at an initial dose of 200 mg/kg than with beractant.